Zonagen (zona) - good buy? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy?

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Anaxagoras who wrote (1695)	1/14/1998 9:02:00 PM
From: Bill Wexler	Read Replies (2) of 7041

You read way too much into the Schering-Plough deal. It doesn't surprise me that the touts keep shifting attention away from Zonagen's fraudulent scheme to promote an ineffective, generic mediaction by claiming that Schering-Plough would not have given Zonagen money if they didn't beleive in Vasomax. First of all (as I have stated many times) a royalty/or licensing agreement does not a great biotech make. Here is an excellent example: biz.yahoo.com XOMA is reputable, and unlike Zonagen, is not engaged in stock fraud. However, despite the numerous licensing deals with the likes of Genentech, etc. its stock is still a poor performer. Licensing deals are meaningless unless the drug in question turns out to be a big seller. Large pharmas enter into many such arrangements...the majority lead nowhere. The upfront cash may help the company cover expenses a little while longer, but does nothing to return value to the shareholder. Schering-Plough's in-house scientists did not study Vasomax. Schering-Plough relied on Zonagen's own studies and claims. Which now brings us to upcoming nasty surprise #2 for Joe Podolski. Stay tuned.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next